Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Hood

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Diabetes Care|November 25, 2003
It can be doneRobert C Hood
Diabetes Technology & Therapeutics|April 19, 2017
Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?Robert C Hood
Health and Quality of Life Outcomes|October 8, 2016
Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trialSamaneh Kabul, Robert C Hood, Ran Duan, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 5, 2021
Treatment Patterns and Outcomes, Before and After Humulin R U-500 Initiation, Among High-Dose Type 2 Diabetes Mellitus Patients in the United StatesRobert C Hood, Sujana Borra, Ludi Fan, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 22, 2022
Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 InsulinJieling Chen, Sujana Borra, Ahong Huang, et al.
Diabetes Research and Clinical Practice|December 25, 2018
Concentrated insulins in current clinical practiceNanette C Schloot, Robert C Hood, Sheila M Corrigan, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2016
EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETESCarol Wysham, Robert C Hood, Mark L Warren, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 28, 2015
TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIALRobert C Hood, Richard F Arakaki, Carol Wysham, et al.
Diabetes, Obesity & Metabolism|February 17, 2023
Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimenJieling Chen, Ludi Fan, Keisha Maughn, et al.
Journal of Diabetes Science and Technology|July 2, 2021
Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 DiabetesXiaosu Ma, Timothy Waterhouse, Liza L Ilag, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Diabetes Care|November 25, 2003
It can be doneRobert C Hood
Diabetes Technology & Therapeutics|April 19, 2017
Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?Robert C Hood
Health and Quality of Life Outcomes|October 8, 2016
Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trialSamaneh Kabul, Robert C Hood, Ran Duan, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 5, 2021
Treatment Patterns and Outcomes, Before and After Humulin R U-500 Initiation, Among High-Dose Type 2 Diabetes Mellitus Patients in the United StatesRobert C Hood, Sujana Borra, Ludi Fan, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 22, 2022
Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 InsulinJieling Chen, Sujana Borra, Ahong Huang, et al.
Diabetes Research and Clinical Practice|December 25, 2018
Concentrated insulins in current clinical practiceNanette C Schloot, Robert C Hood, Sheila M Corrigan, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2016
EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETESCarol Wysham, Robert C Hood, Mark L Warren, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 28, 2015
TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIALRobert C Hood, Richard F Arakaki, Carol Wysham, et al.
Diabetes, Obesity & Metabolism|February 17, 2023
Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimenJieling Chen, Ludi Fan, Keisha Maughn, et al.
Journal of Diabetes Science and Technology|July 2, 2021
Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 DiabetesXiaosu Ma, Timothy Waterhouse, Liza L Ilag, et al.
Pageof 2